28-Feb-2008 - MorphoSys AG

Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich

Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. "We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."

Facts, background information, dossiers
  • antibodies
  • Sigma-Aldrich
  • MorphoSys
  • AbD Serotec
  • Binder
More about MorphoSys
More about Sigma-Aldrich
  • News

    Merck Completes Sigma-Aldrich Acquisition

    Merck announced the completion of its $ 17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry. The completion follows last week’s approval from the European Commission, which was the final antitrust condition required to close the Sigma-Al ... more

    Merck Set to Complete Sigma-Aldrich Acquisition

    Merck announced that following the final approval of the European Commission it is set to complete its $17 billion (€13.1 billion) acquisition of Sigma-Aldrich. The European Commission had granted conditional approval to the acquisition of Sigma-Aldrich on June 15, 2015, subject to the dive ... more

    Merck announces Sigma-Aldrich business sale to Honeywell

    Merck announced that Sigma-Aldrich, the U.S. life science company it plans to acquire, agreed to sell parts of its solvents and inorganics business in Europe to Honeywell in fulfilment of commitments made to the European Union in order to win antitrust approval for its $17 billion acquisiti ... more

  • Companies

    Sigma-Aldrich Chemie GmbH

    more

    Sigma-Aldrich Corp.

    Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high ... more

    Sigma-Aldrich Química, S.A. de C.V.

    Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high ... more